Skip to content
06/16/2026
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Merlintrader Trading Pub

Merlintrader Trading Pub

Biotech catalyst news and analysis. FDA PDUFA tracker

DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Primary Menu
  • Merlintrader
    • About Merlintrader
    • Merlintrader Blog
    • Daily Briefing
    • Daily Watchlist
    • Discord
    • Latest News
    • Small & Medium Caps
    • CHARTSWATCHER 10% OFF !
    • Disclaimer
  • Cannabis Stocks Hub 2026
    • Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
    • Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
  • Space, Defense & AI Hub 2026
    • BlackSky Technology Inc. (NYSE: $BKSY) Stock Hub
    • BigBear.ai Holdings (NYSE: $BBAI)
    • Castellum, Inc. (NYSE American: $CTM) Stock Hub
    • Intuitive Machines (Nasdaq: $LUNR) Stock Hub
    • Ondas Holdings (NASDAQ: $ONDS) Stock Hub
    • Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub
    • Planet Labs PBC (NYSE: $PL)
    • POET Technologies (NASDAQ: $POET): Company Story,
    • Red Cat Holdings (NASDAQ: $RCAT)
    • Redwire Corporation (NYSE: $RDW) Stock Hub
    • Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub
    • Satellogic Inc. (Nasdaq: $SATL)
  • Biotech Stocks Hub
    • ADMA Biologics (Nasdaq: $ADMA)
    • Agios Pharmaceuticals (Nasdaq: $AGIO) Stock Hub
    • Alpha Tau Medical Ltd. (Nasdaq: $DRTS)
    • Altimmune Inc. (Nasdaq: $ALT )
    • Aquestive Therapeutics (Nasdaq: $AQST Stock Hub.
    • Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub
    • BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub
    • Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub
    • Corcept Therapeutics $CORT Stock Hub
    • CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub
    • Cytokinetics, Incorporated (Nasdaq: $CYTK)
    • Fate Therapeutics (Nasdaq: $FATE): Stock Hub
    • Geron Corporation (Nasdaq: $GERN) Stock Hub
    • ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub
    • Iovance Biotherapeutics (Nasdaq: $IOVA)
    • MannKind Corporation (Nasdaq: $MNKD) Stock Hub
    • Microbot Medical Inc. (Nasdaq: $MBOT) Stock Hub
    • Moleculin Biotech (Nasdaq: $MBRX) Stock Hub
    • Novavax, Inc. (Nasdaq: $NVAX) Stock Hub
    • NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub
    • Ocugen, Inc. (Nasdaq: $OCGN) Stock Hub
    • Ocular Therapeutix (Nasdaq: $OCUL) Stock Hub
    • Omeros Corporation (Nasdaq: $OMER): Stock Hub
    • Outlook Therapeutics (Nasdaq: $OTLK): Stock Hub
    • Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub
    • SeaStar Medical Holding Corporation (Nasdaq: $ICU) Stock Hub
    • SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub.
    • Summit Therapeutics (Nasdaq: $SMMT) Stock Hub
    • Travere Therapeutics (Nasdaq: $TVTX)
    • Viridian Therapeutics (Nasdaq: $VRDN)
  • FREE CATALYST CALENDAR
    • Catalyst Total Tracker
  • Merlintrader Travel Pub

Home - Intraday - Jiade Ltd ($JDZG)

  • Intraday

Jiade Ltd ($JDZG)

Jiade is a micro-cap education-support company listed on Nasdaq, best known for providing tutoring and training services for adult and vocational education in China. A strategic cooperation with a South Korea–based AI education brand adds an international angle, but the story still sits at the intersection of cross-border ambitions, regulatory risk and the harsh math of small-cap liquidity.
3 views
JDZG daily chart (Finviz)
Daily Hit — Small-cap education / Asia link

Jiade Limited (JDZG) — tiny China edu name with a South Korea AI-education bridge

Jiade is a micro-cap education-support company listed on Nasdaq, best known for providing tutoring and training services for adult and vocational education in China. A strategic cooperation with a South Korea–based AI education brand adds an international angle, but the story still sits at the intersection of cross-border ambitions, regulatory risk and the harsh math of small-cap liquidity.

Ticker JDZG (Nasdaq) Sector Education support / vocational services Focus China adult education, South Korea AI-cooperation
Snapshot & what the company actually does

Jiade Limited is a Cayman holding company whose operating entities in China provide education support services for adult and continuing education, including exam-oriented tutoring and vocational training. According to the company’s SEC filings, the group works mainly with education partners, helping them recruit and support adult learners and prepare them for nationally recognised exams and skills certifications.1

This is not a big listed university chain. It is a small, asset-light platform that sits between students and training institutions, earning fees by helping adults navigate exams, coursework and the paperwork of continuing education.

  • Business: education support and tutoring for adult / vocational learners in China.
  • Structure: Cayman holding company with operating subsidiaries in mainland China.
  • Listing: JDZG on Nasdaq; very small free float and low average daily volume.
Financial snapshot (latest official numbers)

The most recent detailed financials publicly available at the time of writing are for the six months ended June 30, 2024, filed via a Form 6-K with the SEC.2

  • Revenue for the half-year: approximately RMB 8.9 million (about US$1.23 million at the exchange rate used in the filing).
  • Net income for the half-year: around RMB 5.22 million (roughly US$0.72 million).
  • Cash and cash equivalents as of June 30 2024: about RMB 62.6 million (approximately US$8.62 million).

These figures are not 2026 numbers; they are the last detailed results the company has filed publicly as of early 2026. Any trading or investment decision should assume that conditions may have changed since those dates and must be cross-checked against the latest 6-K, 20-F or other filings.

Why the South Korea link matters: AI, branding and cross-border ambition

The angle that makes Jiade interesting for a small slice of the market is its bridge into South Korea. In 2025 the company signed a strategic cooperation agreement with Chinalink Education Group, an education brand based in South Korea that focuses on AI-assisted learning and cultural exchange programmes. At the start of 2026 the company highlighted this cooperation in a strategic update, presenting it as a way to expand AI-driven education projects and bring overseas branding and content into its Chinese vocational ecosystem.3

The agreement is not a classic “big ticket” M&A deal. Instead, it sketches out cooperation in several fields: developing AI-enabled teaching tools, exploring metaverse-style digital experiences, and promoting composite talent with both technical skills and foreign language abilities. Chinalink’s base in South Korea matters, because it gives Jiade a partner anchored in one of Asia’s most competitive education and technology markets, with relationships spanning local universities and training providers.

For a company of Jiade’s size, even incremental access to South Korean know-how, curriculum design and AI-driven learning tools can be meaningful. It potentially gives Jiade content, brand and technology that differentiate it from purely domestic adult education providers that rely on more traditional teaching formats.

What the filings say about strategy and risk

Jiade’s registration statement and subsequent filings paint a familiar picture for a small China-based education-support name listed in the US. The company sees an opportunity in China’s continuing education and vocational upgrade push, where millions of adults need credentials and updated skills in order to keep up with a changing labour market.1

At the same time, the filings emphasise a long list of risks:

  • Regulatory risk in China: education policy can change quickly, and authorities have already shown they are willing to overhaul large parts of the tutoring industry.
  • Cross-border and data risk: any AI-enabled or cross-border programmes involving South Korea have to respect both Chinese and Korean data and education rules.
  • US listing and compliance risk: as a small foreign issuer, Jiade must stay on top of Nasdaq listing requirements and US reporting standards.

For traders and investors, that combination means the upside case is tightly linked to execution on a niche strategy, while the downside includes both operational and regulatory tail risk.

Balance sheet, scale and the reality of trading a micro-cap

Even if the business produces positive net income at the levels reported in the latest half-year numbers, Jiade remains very small in absolute terms. Revenue and profit are measured in single-digit millions of US dollars, and the market capitalisation sits in micro-cap territory. That has two consequences for anyone looking at the ticker.

First, liquidity and volatility: thin trading can amplify every order, whether it is a small retail order or a single institutional seller exiting. The bid–ask spread can be wide, and intraday moves can look dramatic even when the underlying news flow is quiet.

Second, funding options: small, cross-border education names often rely on a mix of cash on hand, operating cash flow and potential future capital raises, including shelf registrations that allow them to issue equity or other securities over time. Jiade has filed a shelf registration statement to give itself flexibility, but whether that translates into value creation or just dilution depends on execution, market conditions and deal terms.4

Why some traders watch JDZG in 2026

In early 2026, JDZG tends to pop up on screeners for three reasons:

1. A niche angle on AI-education and South Korea. Most AI-education stories investors hear about are either big platform companies or domestic ed-tech names. Jiade’s link with a South Korea–based AI education brand is unusual because it connects a small Chinese adult-education platform with a partner embedded in a different education ecosystem. The cooperation is still at an early stage, but it gives the story a hook that is more international than classic domestic tutoring.

2. Optionality versus risk. With a small market cap and a limited float, any progress on the AI or cross-border front can move the price quickly. The flipside is that setbacks, delays, capital raises or regulatory friction can hit just as hard. This is not a “set and forget” investment; it is more of a high-beta satellite that requires tight risk management.

3. The education-policy cycle. Policy in both China and South Korea continues to emphasise skills, digital literacy and international cooperation in education. That macro backdrop supports the idea of more vocational learning and cross-border programmes, but also means Jiade will always operate under the shadow of policy changes that can redirect funding or reshape what is allowed.

What to watch next

Looking ahead, the practical checklist for JDZG in 2026 is straightforward:

Short term: monitor the next rounds of financial results and any new 6-K filings to see whether revenue from AI-driven or South Korea–linked programmes starts to show up in the numbers. Watch for any updates on how the cooperation with Chinalink is being implemented on the ground – concrete programmes, joint marketing, or the launch of AI teaching tools within Jiade’s existing courses.

Medium term: keep an eye on listing-compliance disclosures, capital plans and any changes in education regulation that might affect adult and vocational providers. The risk/reward on a name like this is as much about the cost of capital and regulatory environment as it is about technology buzzwords.

Sources & verification: core facts and figures in this Daily Hit are based on Jiade Limited’s registration and reporting documents filed with the U.S. Securities and Exchange Commission (including the company’s registration statement and Form 6-K financial results for the six months ended June 30 2024), and on the company’s own press releases and strategic updates regarding its cooperation with a South Korea–based education brand. Always refer to the latest filings on the SEC’s website and to the company’s official investor-relations materials for current information.

Educational-only notice: this Daily Hit is for informational and educational purposes only. It is not investment advice, not a recommendation to buy or sell any security, and not a substitute for independent due diligence. Small-cap and micro-cap stocks can be extremely volatile and illiquid; never risk capital you cannot afford to lose.

Daily Hit — Small cap formazione / asse Asia

Jiade Limited (JDZG) — piccola storia education cinese con un ponte AI verso la Corea del Sud

Jiade è una micro-cap della formazione quotata al Nasdaq, focalizzata sui servizi di supporto all’istruzione per adulti e corsi professionali in Cina. Un accordo di cooperazione strategica con un marchio di education basato in Corea del Sud, specializzato in soluzioni didattiche con AI, aggiunge una dimensione internazionale. Ma la storia resta quella di una realtà molto piccola, che vive fra ambizioni cross-border, rischio regolatorio e la dura realtà della liquidità limitata.

Ticker JDZG (Nasdaq) Settore Servizi educativi / formazione professionale Focus Formazione adulti in Cina, cooperazione AI con Corea del Sud
Snapshot & cosa fa davvero l’azienda

Jiade Limited è una holding registrata alle Cayman, i cui veicoli operativi in Cina forniscono servizi di supporto all’istruzione per adulti e formazione continua, con particolare attenzione alla preparazione agli esami e ai corsi di aggiornamento professionale. In base ai documenti depositati presso la SEC, il gruppo lavora principalmente con partner educativi, aiutandoli a reclutare e supportare studenti adulti e a prepararli per esami e certificazioni di competenze riconosciute a livello nazionale.1

Non stiamo parlando di una grande catena universitaria quotata, ma di una piattaforma leggera che si posiziona fra studenti e istituti di formazione, guadagnando commissioni per facilitare l’accesso agli studi, l’erogazione dei corsi e la gestione della parte più burocratica della formazione continua.

  • Business: supporto didattico e tutoring per studenti adulti / corsi professionali.
  • Struttura: holding alle Cayman con controllate operative nella Cina continentale.
  • Quotazione: JDZG sul Nasdaq; flottante molto ridotto e volumi medi bassi.
Fotografia finanziaria (ultimi dati ufficiali)

Gli ultimi dati finanziari dettagliati disponibili al momento della stesura riguardano il semestre chiuso al 30 giugno 2024, comunicato tramite Form 6-K alla SEC.2

  • Ricavi del semestre: circa 8,9 milioni di RMB (all’incirca 1,23 milioni di USD al cambio utilizzato nel filing).
  • Utile netto del semestre: circa 5,22 milioni di RMB (circa 0,72 milioni di USD).
  • Disponibilità liquide e mezzi equivalenti al 30 giugno 2024: circa 62,6 milioni di RMB (circa 8,62 milioni di USD).

Questi non sono numeri del 2026, ma gli ultimi risultati dettagliati che la società ha reso pubblici alla data attuale. Qualsiasi decisione operativa o di investimento deve partire dal presupposto che lo scenario possa essere cambiato e va sempre confrontata con le più recenti 6-K, 20-F o altre comunicazioni ufficiali.

Perché il legame con la Corea del Sud è rilevante: AI, brand e ambizione cross-border

L’elemento che rende JDZG interessante per una nicchia di trader è il collegamento con la Corea del Sud. Nel 2025 la società ha firmato un accordo di cooperazione strategica con Chinalink Education Group, un marchio educational con base in Corea del Sud focalizzato su programmi di apprendimento assistito dall’intelligenza artificiale e scambi culturali. All’inizio del 2026 questo accordo è stato rimarcato come pilastro di una strategia che punta a espandere progetti formativi guidati dall’AI e a importare contenuti e branding esteri nell’ecosistema di formazione professionale di Jiade.3

Non è una grande acquisizione, ma un quadro di collaborazione in più aree: sviluppo di strumenti didattici supportati da AI, esplorazione di esperienze digitali di tipo “metaverso”, promozione di profili professionali che uniscono competenze tecniche e conoscenza delle lingue straniere. Il fatto che Chinalink abbia le sue radici in Corea del Sud è importante perché la collega a uno dei mercati educativi e tecnologici più competitivi dell’Asia, con relazioni verso università e operatori locali.

Per una realtà delle dimensioni di Jiade, anche un accesso graduale a know-how, progettazione didattica e strumenti di apprendimento basati su AI provenienti dalla Corea del Sud può fare la differenza. Potenzialmente offre contenuti, brand e tecnologia che la distinguono dai provider cinesi focalizzati solo su formazione adulti con modalità più tradizionali.

Cosa emerge dai documenti ufficiali su strategia e rischi

La documentazione di registrazione e i filing successivi descrivono un quadro tipico per una small cap cinese della formazione supportata quotata negli Stati Uniti. Jiade vede un’opportunità nella spinta cinese verso la formazione continua e l’aggiornamento professionale, dove milioni di lavoratori adulti hanno bisogno di nuove certificazioni e competenze per restare competitivi in un mercato del lavoro in rapido cambiamento.1

Allo stesso tempo, nei documenti ufficiali viene sottolineata una lunga lista di rischi:

  • Rischio regolatorio in Cina: le regole sulla formazione possono cambiare velocemente e le autorità hanno già dimostrato di poter ristrutturare interi segmenti del tutoring.
  • Rischio cross-border e dati: qualunque programma con AI o collaborazione Corea–Cina deve rispettare normative su dati personali e istruzione in entrambe le giurisdizioni.
  • Rischio legato alla quotazione USA: come emittente straniero di piccole dimensioni, Jiade deve mantenersi in regola con i requisiti del Nasdaq e con gli standard informativi statunitensi.

Per chi guarda il titolo questo significa che lo scenario positivo dipende molto dalla capacità di esecuzione su una nicchia specifica, mentre lo scenario negativo include rischi operativi e regolatori difficili da modellare in anticipo.

Bilancio, scala e realtà pratica di una micro-cap

Anche se, ai livelli riportati nell’ultimo semestre disponibile, il business genera utile netto, Jiade resta una società molto piccola in termini assoluti. Ricavi e utili si misurano in pochi milioni di dollari e la capitalizzazione di borsa rientra pienamente nel territorio micro-cap. Questo si traduce in due conseguenze concrete.

La prima è liquidità e volatilità: con volumi ridotti ogni ordine pesa, e spread denaro/lettera ampi possono amplificare movimenti intraday anche in assenza di notizie sostanziali.

La seconda riguarda le opzioni di finanziamento: molte realtà cross-border di questo tipo combinano cassa esistente, generazione di cassa operativa e, se necessario, possibili aumenti di capitale abilitati da shelf registration. Jiade ha depositato un prospetto di questo tipo per darsi flessibilità, ma se questo si tradurrà in creazione di valore o sola diluizione dipenderà da execution, condizioni di mercato e termini delle eventuali operazioni.4

Perché JDZG attira l’attenzione di alcuni trader nel 2026

All’inizio del 2026 JDZG compare di tanto in tanto sui radar per tre motivi principali.

1. Angolo di nicchia su AI-education e Corea del Sud. La maggior parte delle storie “AI nella formazione” riguardano grandi piattaforme o nomi ed-tech più noti. Qui invece abbiamo una piccola realtà cinese focalizzata su adulti e percorsi professionali che si aggancia a un partner coreano specializzato in soluzioni didattiche basate su AI. È una narrativa più internazionale rispetto al classico tutoring domestico.

2. Optionalità contro rischio. Con una capitalizzazione ridotta e un flottante limitato, qualsiasi progresso concreto sull’asse AI / Corea può muovere il titolo in modo violento. Il rovescio della medaglia è che ritardi, aumenti di capitale o frizioni regolatorie possono avere un impatto altrettanto brusco. Non è un titolo “buy & hold” da dimenticare in portafoglio: è più un satellite ad alto beta che richiede gestione del rischio molto rigorosa.

3. Ciclo delle politiche educative. Sia in Cina sia in Corea del Sud l’attenzione verso competenze, alfabetizzazione digitale e cooperazione internazionale in ambito education resta elevata. Questo supporta la narrativa su formazione per adulti e programmi cross-border, ma implica anche che Jiade dovrà muoversi sempre all’interno di un quadro regolatorio dinamico.

Cosa monitorare nei prossimi mesi

In pratica, nel 2026 la checklist su JDZG può essere riassunta così:

Nel breve: seguire le prossime comunicazioni contabili e le nuove 6-K per capire se i programmi collegati alla Corea del Sud e alle soluzioni AI iniziano a pesare in modo visibile sui ricavi. Osservare eventuali dettagli su progetti concreti con Chinalink: corsi co-brandizzati, strumenti didattici AI integrati nei percorsi esistenti, iniziative di marketing congiunte.

Nel medio periodo: monitorare gli aggiornamenti sulla conformità ai requisiti di quotazione, i piani di raccolta capitale e le evoluzioni del quadro normativo sulla formazione adulti. Su un titolo di queste dimensioni il rapporto fra costo del capitale, regolazione e execution pesa quanto – se non più – delle etichette “AI” o “metaverso”.

Fonti & verifica: i dati e i fatti riportati in questo Daily Hit provengono dai documenti di registrazione e dai filing di Jiade Limited presso la U.S. Securities and Exchange Commission (inclusi il prospetto di registrazione e il Form 6-K con i risultati per il semestre chiuso al 30 giugno 2024), oltre che dai comunicati stampa e dagli aggiornamenti strategici della società sulla cooperazione con un marchio educational basato in Corea del Sud. Fare sempre riferimento alle versioni più recenti pubblicate sui siti ufficiali della SEC e della società.

Avvertenza educativa: questo contenuto ha finalità esclusivamente informative ed educative. Non costituisce in alcun modo consulenza o raccomandazione di investimento, né sostituisce un’analisi indipendente. Le small e micro-cap possono essere estremamente volatili e poco liquide; non esporsi mai con capitale che non ci si può permettere di perdere.

What do you feel about this?

  • Intraday

Post navigation

Previous: Viking Therapeutics Inc (VKTX)
Next: Neumora Therapeutics Inc ($NMRA) Feb 12 2026

Related Stories

  • Intraday

Actelis Networks ( $ASNS ) – Cyber-Hardened Networking For Critical Infrastructure In 2026

2
  • Defence
  • Intraday

ParaZero ($PRZO) DefendAir intercepts a hostile drone at ~70 mph 

1
  • Intraday

CYN Cyngn Inc

0
  • Intraday

VIVS VivoSim Labs Inc

0
  • Intraday
  • Small Caps Trending

JFBR Jeffs Brands Ltd

3

Trending Now

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC Spy oil inflation 1
  • Editorial

Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC

18
The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question truce Usa Iran 2
  • Editorial

The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question

53
Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen cldx 3
  • Reports Biotech

Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen

77
Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215 nmra 4
  • Reports Biotech

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

70

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.
✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →
✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.
✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.
```
Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

  • Full reports on individual stocks
  • FDA, catalyst and clinical-trial analysis
  • Daily briefings, watchlists and market themes
  • A free archive updated on a regular basis
Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

  • Report completi su singoli titoli
  • Analisi di catalyst, FDA e trial clinici
  • Daily briefing, watchlist e temi di mercato
  • Un archivio gratuito aggiornato con regolarità
Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Merlintrader Newsletter

Stay ahead of the next catalyst

Get market notes, deep-dive updates and catalyst-focused research directly from Merlintrader.

Educational market content only. No spam. You can unsubscribe anytime.
Terms, privacy and disclaimer
DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Scanner for active traders
ChartsWatcher logo

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform
Medved Trader logo

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

Donate via PayPal

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Buy Me a Coffee

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

  • Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
  • ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
  • Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
  • Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
  • Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
  • Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Terms and Conditions
Cookie Policy
Privacy Policy
Merlintrader is a personal blog curated by Horacio F. Greco. Contact: info@merlintrader.com. No professional financial advice.
Do Not Sell or Share My Personal Information